YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Eli Lilly Aims for $800-Million Pill By 2010


December 11, 2008 | The media took contrasting views of Eli Lilly’s lowered financial expectations for 2009. Bloomberg said “Lilly Below-Estimate Forecast Shows Drugmaker Slump,” whereas Forbes thought “Lilly looks healthy.” The difference is largely due to whether one includes the costs of recently acquiring ImClone for $6.5 billion. Lilly also said it planned to reduce its costs of new drug development from $1.2 billion to $800 million by 2010. Read more and more.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.